MedTrace Logo

Pembrolizumab in Combination With Chemotherapy and Image-Guided Surgery for Malignant Pleural Mesothelioma (MPM)

NCT03760575 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2025-12-04

No results posted yet for this study

Summary

The study is a single-arm phase I trial to evaluate the safety, feasibility, and preliminary efficacy of the addition of pembrolizumab and image-guided resection to surgical therapy and chemotherapy for malignant pleural mesothelioma (MPM).

Conditions

  • Mesotheliomas Pleural

Interventions

DRUG

Pembrolizumab

Pembrolizumab 200mg via IV infusion every 3 weeks for 2 cycles 3 pre-surgery, for 4 cycles post-surgery and then every 3 weeks during maintenance.

PROCEDURE

Indocyanine Green (ICG) Image-Guided Surgery

Standard surgery with image guided resection.

DRUG

Cisplatin

75 mg/m2 every 3 weeks via IV infusion for 4 cycles post-surgery.

DRUG

Pemetrexed

500 mg/m2 every 3 weeks via IV infusion for 4 cycles post-surgery.

Sponsors & Collaborators

  • Abramson Cancer Center at Penn Medicine

    lead OTHER

Principal Investigators

  • Corey Langer, MD · University of Pennsylvania Abramson Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-10
Primary Completion
2027-02-01
Completion
2027-02-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03760575 on ClinicalTrials.gov